Endpoints for clinical trials in young children with cystic fibrosis

Stephanie D. Davis, Alan S. Brody, Mary J. Emond, Lyndia C. Brumback, Margaret Rosenfeld

Research output: Contribution to journalArticle

67 Scopus citations


The availability of sensitive, reproducible, and feasible outcome measures for quantifying lung disease in children with cystic fibrosis (CF) younger than 6 years is critical to the conduct of clinical trials in this important population. Historically, identifying and quantifying the presence of lung disease in very young children with CF was hampered by a lack of reproducible measures of lung function or lung pathology. Over the past 10 years, significant progress has led to physiologic, anatomic, and bronchoscopic measures that may serve as endpoints for future intervention trials. These endpoints include infant and preschool lung function testing, computed tomography of the chest, and bronchoalveolar lavage markers of inflammation and infection. Much progress has occurred in standardizing lung function testing, which is essential for multicenter collaboration. Pulmonary exacerbation has the potential to serve as a clinical endpoint; however, there is currently no standardized definition in children with CF younger than 6 years. Further development of these outcomes measures will enable clinical trials in the youngest CF population with the objective of improving long-term prognosis.

Original languageEnglish (US)
Pages (from-to)418-430
Number of pages13
JournalProceedings of the American Thoracic Society
Issue number4
StatePublished - Aug 2007


  • Bronchoalveolar lavage
  • Child
  • Computed tomography scanners
  • Infant
  • Preschool
  • Respiratory function tests
  • X-ray

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Endpoints for clinical trials in young children with cystic fibrosis'. Together they form a unique fingerprint.

  • Cite this